The Component You Never Think About: India's Place in the Global Injectable Supply Chain

Every vaccine vial and injectable drug ships with a small aluminium seal on top, and a surprising share of the world’s supply of those seals is made in India. The country is widely described as the pharmacy of the world for its finished-drug exports, but the same industrial base quietly produces the primary packaging those drugs depend on: the glass vials, rubber stoppers, and aluminium closures that keep a sterile product sterile. It is one of the least visible and most essential links in global health.

The reason this matters now is that the pandemic exposed how fragile single-source packaging supply chains can be. When billions of vaccine doses had to be filled in a matter of months, the bottleneck was sometimes not the drug substance but the vials and the closures to seal them. Buyers learned, expensively, that primary packaging is a strategic input, not a commodity to be sourced at the last minute.

Why packaging followed pharma to India

India’s strength in pharmaceutical packaging grew alongside its generics industry. As domestic drug makers scaled, a supporting ecosystem of vial, stopper, and seal manufacturers grew with them, close to the fill-finish lines and operating under the same regulatory pressure. India’s commerce ministry and industry bodies put the country’s share of global generic medicine supply at roughly a fifth by volume, and India is routinely described as supplying a majority of the world’s vaccine doses by volume. A packaging supply base matured to serve that demand.

Proximity turned out to matter for reasons that have little to do with freight cost. Primary packaging is qualified against a customer’s specific vial and stopper, and qualification is iterative: samples, capping trials, dimensional argument, a second round of samples. A supplier three hours from the fill-finish site can put an engineer on the line. A supplier eight time zones away sends an email and waits. That is an underrated part of why the sector clustered in and around the pharmaceutical belts of Maharashtra and Gujarat, within a few hours of Mumbai’s ports and airports.

That proximity produced suppliers who understand the regulated market from the inside. A closure manufacturer in India is typically certified to the same international standards its customers must meet, ISO 15378 for primary packaging GMP among them, and is accustomed to customer and regulatory audits as a routine part of business.

What the pandemic actually exposed

The abstract version of this argument is that supply chains are fragile. The documented version is more specific and more useful.

Filling capacity was never the only constraint on vaccine supply in 2020 and 2021. The containers were. In June 2020 the US Biomedical Advanced Research and Development Authority committed $204 million to Corning to expand production capacity for pharmaceutical glass vials, one of several public awards made specifically to build packaging capacity rather than drug capacity. Governments do not fund vial factories when vials are easy to buy.

The input side showed the same pattern from the opposite direction. In April 2021 the chief executive of the Serum Institute of India publicly appealed to the United States to release exports of raw materials needed for vaccine manufacture, after export restrictions were applied under the Defense Production Act. The items in question were consumables and components rather than the vaccine itself.

Both episodes make the same point. When demand steps up by an order of magnitude, the constraint moves to whichever input has the longest lead time and the fewest qualified sources, and primary packaging has both characteristics at once. Qualifying a new closure supplier involves samples, capping trials, integrity data, and in many cases a regulatory change filing, and none of those steps compress well under pressure.

What the closure business actually looks like

The economics reward scale and consistency. A pharmaceutical filling line consumes seals by the hundred per minute, so a closure supplier has to deliver enormous volume at a defect rate measured in parts per million, lot after lot. The product range is wide as well: flip-off seals for vaccines, pull-ring and tear-off seals for different opening needs, and pilfer-proof caps for tamper evidence, each across a span of neck sizes from roughly 13 mm to 34 mm.

The physical process is unglamorous, and it explains the economics better than any market figure. Thin aluminium strip arrives as coil, is lacquered and printed while still flat, then deep-drawn and cut into shells on presses running at high stroke rates. Where the closure carries a plastic top, the polypropylene component is injection-moulded and assembled to the metal shell. The shells are washed to control particulates, assembled in a classified room, and inspected by camera at line speed before packing.

At a fraction of a rupee per piece, every one of those steps has to be automated, because a single manual handling operation costs more than the part it handles. The same arithmetic forces inspection inline rather than downstream: sorting a suspect lot after the fact costs a multiple of what the lot is worth, and the customer’s exposure is larger again, because the place the defect gets discovered is their filling line. This is why credible closure suppliers converge on roughly the same physical shape. There is no low-volume version of this business that also hits the defect rate.

This is a high-volume, high-precision, low-unit-cost business, which is exactly the kind of manufacturing India does well. Producers such as Autofits run plants turning out billions of seals a year and supply more than 150 pharmaceutical companies across domestic and export markets, which tells you the output meets international expectations rather than only local ones.

Why the paperwork travels better than the parts

What surprises people outside the industry is how much of a closure supplier’s value is documentary rather than physical.

A pharmaceutical company filing a marketing application has to describe its container closure system in detail: materials, dimensions, manufacturing process, and controls. Much of that information is the packaging manufacturer’s own process knowledge, and no manufacturer wants it circulating in every customer’s dossier. The mechanism that resolves the conflict is the Drug Master File, a confidential submission made directly to the regulator by the component manufacturer, which the drug applicant then references by number without ever seeing the contents. The regulator reads both halves. The customer reads neither, and does not need to.

For an Indian supplier selling into regulated markets, holding that file is much of the difference between being a vendor and being a qualified source. The same logic runs through the standards. A closure sold internationally has to satisfy the vial and cap geometry standards in the ISO 8362 series, the material and heavy-metal limits that apply to primary packaging, and whichever pharmacopoeia the customer’s market runs on, frequently more than one at a time, with CDSCO requirements sitting alongside US FDA and EMA expectations. Building a quality system that satisfies several compendia at once is a fixed cost with a long payback, and it is difficult for a new entrant to replicate quickly, which is a large part of why this industry consolidates around a relatively small number of names.

The strategic lesson for buyers

For pharmaceutical companies and the health systems behind them, the supply-chain takeaway from the last few years is to treat primary packaging as a qualified, diversified input:

• Qualify the packaging supplier as rigorously as the drug-substance supplier. A closure is regulated primary packaging, and a failure there stops a batch as surely as a failure in the active ingredient.
• Qualify the site, not the company. A group with several plants may make your item at only one of them. The certificate, the audit, and the change agreement should all name that site.
• Avoid single sourcing on critical closures. The firms that weathered the pandemic best had more than one qualified seal supplier, and had qualified the second before they needed it.
• Ask where the aluminium comes from. Closure stock is a globally traded input, and a supplier’s continuity depends on their coil supply as much as on their presses. Second-tier disruption reaches you through a supplier who looks entirely healthy on every metric you monitor.
• Look for certified capacity, not just low price. A supplier with proven volume and a current ISO 15378 certificate is a continuity asset, not just a line item.
• Value geographic diversity. Several suppliers in one industrial cluster is not diversity.

The takeaway

The aluminium seal on a vaccine vial is a near-perfect example of essential, invisible manufacturing, and India has become one of the places the world relies on to make it. The country’s role in the injectable supply chain runs deeper than finished drugs into the packaging that protects them. For buyers, the practical conclusion is straightforward: the closure deserves the same supply-chain discipline as the medicine, and the certified, high-volume producers that have grown up alongside India’s pharma industry are a meaningful part of how that discipline gets met.

This article was written by the team at Autofits, a Nashik-based manufacturer of pharmaceutical vial seals and pilfer-proof caps serving customers in India and export markets.